Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity
Hind Rafei, May Daher, Katayoun Rezvani
British Journal of Haematology (2020) Vol. 193, Iss. 2, pp. 216-230
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zengfu Zhang, Xu Liu, Dawei Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 344
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
David Marín, Ye Li, Rafet Başar, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 772-784
Open Access | Times Cited: 153
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
Qijie Zhao, Yu Jiang, Shixin Xiang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 113
CAR-NK Cells in the Treatment of Solid Tumors
Ewa Wrona, Maciej Borowiec, Piotr Potemski
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5899-5899
Open Access | Times Cited: 105
The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
Yanlin Yu
Cancers (2023) Vol. 15, Iss. 8, pp. 2323-2323
Open Access | Times Cited: 51
Synapse-tuned CARs enhance immune cell anti-tumor activity
Peter Chockley, Jorge Ibañez-Vega, Giedre Krenciute, et al.
Nature Biotechnology (2023) Vol. 41, Iss. 10, pp. 1434-1445
Open Access | Times Cited: 43
Engineering the next generation of CAR-NK immunotherapies
Alexander Biederstädt, Katayoun Rezvani
International Journal of Hematology (2021) Vol. 114, Iss. 5, pp. 554-571
Open Access | Times Cited: 64
Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects
Reza Elahi, Amir Hossein Heidary, Kaveh Hadiloo, et al.
Stem Cell Reviews and Reports (2021) Vol. 17, Iss. 6, pp. 2081-2106
Open Access | Times Cited: 62
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
Hongwen Li, Wenting Song, Zhaoming Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 58
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Shweta Joshi, Andrew B. Sharabi
Pharmacology & Therapeutics (2022) Vol. 235, pp. 108114-108114
Open Access | Times Cited: 52
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
Andreia Maia, Mubin Tarannum, Joana R. Lérias, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 451-451
Open Access | Times Cited: 11
CAR T cells: Building on the CD19 paradigm
Anat Globerson Levin, Isabelle Rivière, Zelig Eshhar, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 9, pp. 2151-2163
Open Access | Times Cited: 54
Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages
Hamidreza Ebrahimiyan, Amirhossein Tamimi, Bahareh Shokoohian, et al.
International Immunopharmacology (2022) Vol. 106, pp. 108587-108587
Closed Access | Times Cited: 36
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Xiao Wang, Xuejiao Yang, Xiang Yuan, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 35
How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy
Alexander Biederstädt, Katayoun Rezvani
Blood (2022) Vol. 141, Iss. 1, pp. 22-38
Open Access | Times Cited: 30
Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
Kangdi Yang, Yuze Zhao, Guanqun Sun, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 19
Cancer stem cells targets and combined therapies to prevent cancer recurrence
Pawan Kumar Raghav, Zoya Mann
Life Sciences (2021) Vol. 277, pp. 119465-119465
Closed Access | Times Cited: 35
NK Cell-Based Immunotherapy in Colorectal Cancer
Mariella Della Chiesa, Chiara Setti, Chiara Giordano, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1033-1033
Open Access | Times Cited: 25
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
Ali Keshavarz, Ali Salehi, Setareh Khosravi, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 24
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Farhoodeh Ghaedrahmati, Nafiseh Esmaeil, Maryam Abbaspour
Cancer Communications (2022) Vol. 43, Iss. 2, pp. 177-213
Open Access | Times Cited: 23
Engineered NK Cells Against Cancer and Their Potential Applications Beyond
Maria Karvouni, Marcos Vidal-Manrique, Andreas Lundqvist, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond
Anna Aureli, Beatrice Marziani, Adriano Venditti, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3346-3346
Open Access | Times Cited: 15
Human NK cells and cancer
Claudia Cantoni, Michela Falco, Massimo Vitale, et al.
OncoImmunology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
A framework integrating multiscale in-silico modeling and experimental data predicts CD33 CAR-NK cytotoxicity across target cell types
Saeed Ahmad, Kun Xing, Harshana Rajakaruna, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
CAR-NK cell therapy: a potential antiviral platform
Ming-Hao Lin, Lijuan Hu, Jeffrey S. Miller, et al.
Science Bulletin (2025)
Closed Access
Page 1 - Next Page

Scroll to top